



illumina (San Diego) has announced the appointment of **Frances Arnold** (left) to the company's board of directors. Arnold manages a research group at the California Institute of Technology and is the director of the Donna and Benjamin M. Rosen Bioengineering Center. She joined the California Institute of Technology in 1986 and has served as a visiting associate, assistant professor, professor and director. Her laboratory focuses on protein engineering by directed evolution, with applications in alternative energy, chemicals and medicine.

"We are very pleased to welcome Dr. Arnold to our board and look forward to leveraging her experience and expertise in life sciences and medicine," said illumina CEO Jay Flatley. "We value the perspective and passion that she will bring to the role as we plan for growth in our clinical and research markets."

Novan (Durham, NC, USA) has announced that director **Robert A. Ingram** has been named chairman of the company's board of directors, succeeding founding investor **Neal Hunter** who is stepping down from the board after eight years. In addition, **Robert Keegan**, operating partner of private equity firm Friedman, Fleischer & Lowe and the former chairman and CEO of The Goodyear Tire & Rubber Company, has been appointed to the board to replace Novan cofounder **Mark Schoenfisch**, who is stepping down after ten years.

Regenerative medicine company TissueGene (Rockville, MD, USA) has announced the appointment of **Gurdyal Kalsi** as chief medical officer and senior vice president, clinical development and medical affairs. Kalsi most recently served as corporate vice president for clinical development and medical affairs at Emergent BioSolutions. Previously, he was head of medical and regulatory affairs at MDS Pharma.

Onxeo (Paris) has announced that **Jean-Pierre Kinet** and **Jean-Pierre Bizzari** have been appointed observers to its board of directors effective immediately, with appointments as full board members to be submitted at the next annual shareholders meeting. Kinet is a founder of two biotech companies, AB Science and Astarix, and is currently professor of pathology at Harvard Medical School. Bizzari was most recently executive vice president and group head, clinical oncology development at Celgene and is a board member at Transgene, Halozyme Therapeutics and Celator Pharmaceuticals.



Andrew Phillips (left) has been appointed CSO of C4 Therapeutics (Cambridge, MA, USA). He was most recently senior director, Center for Development of Therapeutics at the

Broad Institute of MIT and Harvard, where he led overall therapeutic efforts and provided strategic leadership for a number of major partnerships.

Northwest Biotherapeutics (Bethesda, MD, USA) has expanded its board through the appointments of **Susan Bayh** and **Cofer Black** as independent directors. Bayh brings 25 years of industry experience, having served on the boards of Wellpoint as well as eight public biotech companies. Black brings extensive experience in cybersecurity and counterintelligence after a 28-year career in the CIA, including as director of the agency's Counterterrorist Center. Since 2009, he has served as vice president for global operations at Raytheon Blackbird.

Genomics company Human Longevity (San Diego) has announced the appointments of **Kenneth J. Bloom** as head of oncology and immunotherapy and **Stephen P. Schoenberger** as head of cancer vaccines. Bloom has more than 30 years of clinical and business experience, most recently as chief medical officer at GE Healthcare. Prior to that, he was president and CEO of Clariant Pathology Services. Schoenberger is currently professor in cellular immunology at the La Jolla Institute for Allergy and Immunology and an adjunct professor of medicine in the division of hematology and oncology at the University of California, San Diego, Moores Cancer Center.

Voyager Therapeutics (Cambridge, MA, USA) has announced the promotion of **Jeff Goater**, former senior vice president of finance and business development, to chief financial officer. Goater has more than 15 years of business development and financial experience in the biotech industry. He spent nearly a decade on

Wall Street, most recently as a managing director at Evercore Partners.

Nuritas (Dublin) has appointed **George Gunn** as chairman of its board of directors. A member of Novartis's global executive committee, Gunn led the company's animal health division from 2004 until early 2015, served as division head for Novartis consumer health from 2008 to 2011 and was the head of corporate social responsibility from 2011 to 2014.

Steve Hoerter has been named to the newly created position of chief commercial officer at Agios Pharmaceuticals (Cambridge, MA, USA). He has over 20 years of global pharma and biotech experience, most recently as executive vice president and chief commercial officer at Clovis Oncology. Previously, he held senior commercial roles at Genentech and Roche.



Innova Biosciences (Cambridge, UK) has announced the appointment of **Steve Howell** (left) to the board of directors. Howell has over 20 years of life sciences enterprise experience. He was director of business development at Alere and research director at Unipath before founding investment company Innova Partnerships in 2006. He is currently a non-executive director of Reminova and Relaymed, and is visiting professor of commercial innovation at King's College London.